All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Legal Immunity Offered to Makers of Ebola Vaccines in the US

December 11, 2014
By Pharmaceutical Technology Editors
News
Article

US Department of Health and Human Services announced a declaration to provide immunity to legal claims made in the US in relation to three investigational Ebola vaccines.

 

On December 9, 2014, US Department of Health and Human Services (HHS) announced a declaration under the Public Readiness and Emergency Preparedness (PREP) Act to protect drug makers in the development of Ebola vaccines. Fujifilm, GSK, Tekmira, and recently, Merck and Newlink, have entered into the race for approvals of investigational Ebola vaccines in response to the recent outbreak in West Africa.

According to the most recent updates from the CDC, there have been almost 18,000 total cases and over 6300 deaths related to the 2014 outbreak. The largest outbreak of Ebola in history has caused companies to push investigational drugs to gain agency approvals and begin distributing vaccines worldwide, especially in the most affected areas. With reduced testing, development, and approval periods, HHS announced that the PREP Act will protect three vaccine candidates from legal claims made in relation to manufacturing, testing, development, distribution, and administration. GSK’s ChAd3-EBO-Z, NewLink’s rVsV-ZEBOV-GP, and Janssen’s Ad26.ZEBOV/MVA-BN-Filo vaccines will be protected under this declaration, with the hopes that there will be incentives to continue research and development of vaccines for use against Ebola.

“My strong hope in issuing this PREP Act declaration in the United States is that other nations will also enact appropriate liability protection and compensation legislation. As a global community, we must ensure that legitimate concerns about liability do not hold back the possibility of developing an Ebola vaccine, an essential strategy in our global response to the Ebola epidemic in West Africa,” said Health and Human Services Secretary Sylvia M. Burwell, in a press release.

The PREP Act protects from liability, except in the case of willful misconduct. In the past, the PREP Act has been used to protect H5N1 and H1N1 vaccines, and anthrax, botulism, and smallpox countermeasures.

Sources:
HHSPHE

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Tore Bergsteiner
AI Boosts Early Disease Detection and Diagnostic Accuracy
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Key Leaders at BIO 2025 Respond to Continuing Political Shifts
Ask the Expert: Adventitious Contamination Control
Ask the Expert: Adventitious Contamination Control
Behind the Headlines, Episode 19: CGT Cost Pressures, BioNTech’s CureVac Move, and Spain’s CAR-T Model
Behind the Headlines, Episode 19: CGT Cost Pressures, BioNTech’s CureVac Move, and Spain’s CAR-T Model
BIO 2025: Pulmonary Drug Delivery
BIO 2025: Pulmonary Drug Delivery
Behind the Headlines, Episode 18
Behind the Headlines, Episode 18: Sanofi, GSK Go Big in M&A, mRNA Momentum Falters, and More
A CDMO’s Role in API Quality
A CDMO’s Role in API Quality
CPHI Americas 2025: The Evolving Role of the CDMO
CPHI Americas 2025: The Evolving Role of the CDMO
Drug Digest: Patient Preference Drives Solid Dosage Trends
Drug Digest: Patient Preference Drives Solid Dosage Trends
Related Content
Advertisement

Young man having asthma attack or choking suffering from respiration problems | Image Credit: © Feodora - stock.adobe.com

UK Anaphylaxis Nasal Spray Approval Helps Reshape Emergency Allergy Treatment

Christopher Cole
July 18th 2025
Article

Newly approved needle-free adrenaline spray offers longer shelf life, better stability, and easier use, signaling a shift in emergency drug delivery design.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


Kyiv, Ukraine - December 22, 2020: Backlit single shot image of GlaxoSmithKline logo on tv screen with a hand holding an Covid-19 vaccine concept | Image Credit: © Олександр Луценко - stock.adobe.com

FDA Approves Shingrix Prefilled Syringe to Simplify Vaccine Administration

Christopher Cole
July 17th 2025
Article


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


ADELAIDE, SOUTH AUSTRALIA. - On November 15, 2018. – The University of South Australia is a public university, it is main campus is located on North Terrace in the Adelaide city centre | Image Credit: © arliftatoz2205 - stock.adobe.com

Why You Should Know About a New Weekly Injectable for Parkinson’s

Christopher Cole
July 15th 2025
Article

Biodegradable weekly implant delivers stable levodopa levels, aiming to streamline Parkinson’s care while reshaping drug reformulation and delivery strategies.


Thornhill, Ontario, Canada - October 31, 2020: LEO Pharma Canada sign outside their head office building in Thornhill, Ontario, Canada. LEO Pharma AS is a multinational Danish pharmaceutical company | Image Credit: © JHVEPhoto - stock.adobe.com.

LEO Pharma Takes Over Global Development of Spevigo for Rare Skin Disease GPP

Christopher Cole
July 14th 2025
Article

The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.

Related Content
PharmTech News
|
Manufacturing
|
Quality Systems
|
Formulation and Drug Delivery
|
Dosage Forms
|
Manufacturing, Biologic Drugs
Advertisement

Young man having asthma attack or choking suffering from respiration problems | Image Credit: © Feodora - stock.adobe.com

UK Anaphylaxis Nasal Spray Approval Helps Reshape Emergency Allergy Treatment

Christopher Cole
July 18th 2025
Article

Newly approved needle-free adrenaline spray offers longer shelf life, better stability, and easier use, signaling a shift in emergency drug delivery design.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


Kyiv, Ukraine - December 22, 2020: Backlit single shot image of GlaxoSmithKline logo on tv screen with a hand holding an Covid-19 vaccine concept | Image Credit: © Олександр Луценко - stock.adobe.com

FDA Approves Shingrix Prefilled Syringe to Simplify Vaccine Administration

Christopher Cole
July 17th 2025
Article


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


ADELAIDE, SOUTH AUSTRALIA. - On November 15, 2018. – The University of South Australia is a public university, it is main campus is located on North Terrace in the Adelaide city centre | Image Credit: © arliftatoz2205 - stock.adobe.com

Why You Should Know About a New Weekly Injectable for Parkinson’s

Christopher Cole
July 15th 2025
Article

Biodegradable weekly implant delivers stable levodopa levels, aiming to streamline Parkinson’s care while reshaping drug reformulation and delivery strategies.


Thornhill, Ontario, Canada - October 31, 2020: LEO Pharma Canada sign outside their head office building in Thornhill, Ontario, Canada. LEO Pharma AS is a multinational Danish pharmaceutical company | Image Credit: © JHVEPhoto - stock.adobe.com.

LEO Pharma Takes Over Global Development of Spevigo for Rare Skin Disease GPP

Christopher Cole
July 14th 2025
Article

The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.

Advertisement
Advertisement
Advertisement
x
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.